Corporate Banner
Satellite Banner
RNAi
Scientific Community
 
Join | Sign in
Home>Videos>This Video
  Videos

Return

Extracorporeal Elimination of Circulating Exosomes as a Therapeutic Adjunct to Address Infectious Disease and Cancer
SelectBio

The Aethlon Hemopurifier® is a first-in-class device that targets the rapid elimination of infectious disease and cancer glycopathogens from circulation. In cancer, the Hemopurifier has been demonstrated to capture exosomes underlying lymphoma, melanoma, ovarian, and breast cancer. These microvesicular particles trigger apoptosis of immune cells and have been reported to facilitate tumor growth, metastasis, and the development of drug resistance. In design, the Hemopurifier consists of the affinity lectin Galanthus nivalis agglutinin (GNA) immobilized in the outer-capillary space of plasma membrane technologies. The resulting mechanism provides selective target elimination as GNA binds high mannose signatures abundant on the surface of exosomes and viral glycoproteins. Studies of hepatitis c (HCV) infected patients receiving a three-treatment Hemopurifier protocol combined with interferon-based standard of care resulted in undetectable HCV in as little as seven days in hard-to-treat genotype-1 patients. The studies also documented the ability of the Hemopurifier to capture as many as 300 billion HCV copies during a single six- hour treatment. The FDA recently approved an IDE that allows for the initiation of US feasibility studies.

Request more information
Company product page


Access to this article and other content is for registered users.

Join the Technology Networks Community

  • Access to the latest scientific news, products and research through Technology Networks
  • Upload and share your posters on ePosters
  • View a library of 1,800+ scientific and medical posters
  • A library of 3,000+ scientific videos on LabTube


Sign In



Forgotten your details? Click Here
If you already have an account with Technology Networks, please use your existing login details. If you do not yet have an account please join here.

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Personalized Screening for Ovarian Cancer
With 60% of women diagnosed with ovarian cancer dying within five years of diagnosis there has been considerable efforts to try to detect the disease at an earlier stage.
Potential New Class of Cancer Drugs
Scientists have found a way to stop cancer cell growth by targeting the Warburg Effect, a trait of cancer cell metabolism that scientists have been eager to exploit.
Major Step for Implantable Drug-Delivery Device
MIT spinout signs deal to commercialize microchips that release therapeutics inside the body.
Delivering Drugs to the Right Place
Thomas Weimbs has developed a targeted drug delivery method that could potentially slow the progression of polycystic kidney disease.
Study Finds Addition of Epigenetic Data Improves Predictions of Complex Traits
Researchers reported that combining genetic and epigenetic associations can bolster phenotypic predictions.
Remote-Controlled Drug Delivery
A team of researchers has created a new implantable drug-delivery system using nanowires that can be wirelessly controlled.
Stopping a Single Enzyme Could Help Treat Leukemia
EPFL scientists show how inactivating a single enzyme could effectively eradicate an aggressive form of leukemia. The principles could apply to other cancers as well.
Evo-Engineered CRISPR-Cas9s Hit More Gene-Editing Targets
Scientists have engineered a more effective CRISPR- Cas9 system paving the way for more advanced applications.
Smart Insulin Patch Could Replace Painful Injections for Diabetes
A joint effort between diabetes doctors and biomedical engineers could revolutionize how people with diabetes keep their blood sugar levels in check.
Reducing Uncertainties in Genetic Tests
Breast cancer-associated gene study shows potential to sort out harmful and harmless variants.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters